Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
coPMLA-Me50H50
- Development stage
- Preclinical
- Lead developer
- Cedars-Sinai
- Modality
- Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
coPMLA-Me50H50 is a biodegradable, nontoxic, and nonimmunogenic copolymer derived from poly(β, L-malic acid) (PMLA) of microbial origin, where 50% of the pendant carboxyl groups are methylated. Developed by researchers at Cedars-Sinai Medical Center and the Universitat Politècnica de Catalunya, this copolymer is designed to serve as a versatile nanoconjugate platform for tumor-targeted drug delivery, particularly for brain and breast cancers. coPMLA-Me50H50 exhibits pH-dependent membranolytic activity, allowing it to disrupt endosomal membranes at acidic pH (such as pH 5.0) to facilitate cytoplasmic delivery of attached therapeutic payloads (such as chemotherapeutics, peptides, or oligonucleotides) while bypassing the plasma membrane.
- Other names
- coPMLA-Me(50)H(50)partially methylated poly(beta,L-malic acid) copolyester (50% methylated)poly(beta,L-malic acid) 50% methyl ester
Beyond the preview
Go deeper on coPMLA-Me50H50.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on coPMLA-Me50H50.